Connection
Aaron Michels to Antibodies, Monoclonal
This is a "connection" page, showing publications Aaron Michels has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.472 |
|
|
|
-
Akturk HK, Michels AW. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes. 2020 08; 27(4):187-193.
Score: 0.472
-
Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019 09; 36(9):1075-1081.
Score: 0.438
-
Akturk HK, Alkanani A, Zhao Z, Yu L, Michels AW. PD-1 Inhibitor Immune-Related Adverse Events in Patients With Preexisting Endocrine Autoimmunity. J Clin Endocrinol Metab. 2018 10 01; 103(10):3589-3592.
Score: 0.416
-
Zhang L, Crawford F, Yu L, Michels A, Nakayama M, Davidson HW, Kappler JW, Eisenbarth GS. Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):2656-61.
Score: 0.075
-
Michels AW. Targeting the trimolecular complex. Clin Immunol. 2013 Dec; 149(3):339-44.
Score: 0.071